| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 60/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | Bortezomib |
| Appearance | White Powder |
| CAS NO. | 179324-69-7 |
| MF | C19H25BN4O4 |
| Storage | Keep in a cool, dry, dark location |
Bortezomib is a potent and selective proteasome inhibitor with significant applications in the treatment of multiple myeloma and mantle cell leukemia. Its primary function is to disrupt the protein degradation process within cancer cells, leading to cell death and improved patient outcomes.
Cancer Treatment: Bortezomib is primarily used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It works by inhibiting the proteasome, which disrupts the survival and growth of myeloma cells.
Combination Therapy: It is often administered in combination with other therapeutic agents , to enhance its efficacy and improve patient outcomes.
Mantel Cell Leukemia: Bortezomib has also shown promise in the treatment of mantle cell leukemia, a rare and aggressive form of non-Hodgkin's lymphoma.
Proteasome Inhibition: By inhibiting the proteasome, Bortezomib disrupts the normal protein degradation process within cells. This leads to the accumulation of damaged or abnormal proteins, which triggers cell death (apoptosis) in cancer cells.
Anti-Inflammatory Effects: In addition to its direct antitumor activity, Bortezomib has been shown to exhibit anti-inflammatory properties. This can help reduce inflammation and associated symptoms in some cancer patients.
Modulation of Immune Response: By affecting the proteasome, Bortezomib can also modulate the immune response, potentially enhancing the body's ability to recognize and attack cancer cells.
){kind=link}